Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jul
21
2022
FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) Sheppard, Mullin, Richter & Hampton LLP
Oct
13
2022
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
New Set Of Guidance From FDA Provides Clarity On Digital Health Policies, Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Oct
30
2019
BREAKING NEWS: USDA Releases Interim Final Hemp Rule Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2023
FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
How FDA is Reacting to the Coronavirus, and 2020 Regulatory Priorities Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products Sheppard, Mullin, Richter & Hampton LLP
Oct
17
2023
United Cannabis Corporation v. Pure Hemp Collective Inc. Sheppard, Mullin, Richter & Hampton LLP
May
11
2020
The Expansion of Cardiovascular Procedures in the ASC Setting Sheppard, Mullin, Richter & Hampton LLP
Oct
25
2023
Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2020
FDA Announces Plans to Resume Domestic On-site Inspections Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2011
New Defense Authorization Act Imposes Buy American Act Mandate for Photovoltaics Sheppard, Mullin, Richter & Hampton LLP
Sep
28
2021
Nota Bene Episode 145: Tuna Sustainability: A Model Bigger than its Niche with ISSF President Susan Jackson [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2021
California Broadens Security and Breach Laws, Includes Genetic Data Sheppard, Mullin, Richter & Hampton LLP
Nov
2
2018
OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny Sheppard, Mullin, Richter & Hampton LLP
Jan
4
2022
Cannabis Legislation Year-in-Review Sheppard, Mullin, Richter & Hampton LLP
Feb
11
2022
Federal Cannabis Reform – Is 2022 the Year? Sheppard, Mullin, Richter & Hampton LLP
Apr
4
2022
The House Does It Again: MORE Act Ready for Senate Action Sheppard, Mullin, Richter & Hampton LLP
May
8
2019
AAFCO Issues Updated Guidelines Regarding Hemp in Animal Food Sheppard, Mullin, Richter & Hampton LLP
Jun
13
2022
States Target Infant Formula Price Gouging Sheppard, Mullin, Richter & Hampton LLP
May
20
2019
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
PFAS Regulations Could Open Floodgates to Prop 65 Enforcement – Assess & Manage Your Exposure Now Sheppard, Mullin, Richter & Hampton LLP
Dec
16
2014
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
CBD Industry Beware: The False Labeling Class Action Has Arrived Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2019
Third Circuit Holds that SLUSA Does Not Preclude Class Action Opt-Outs from Pursuing Individual Actions Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2019
FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2020
FCPA Landmines Beneath the Surface of the COVID-19 Crisis - May 6 Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins